Table 2. Antimicrobial resistance of C. acnes in acne patients in other countries, in the published literature (1990-2022). Studies including at least 100 patients are shown.
| Study period | Country | Acne patients, n | Any antibiotic resistance, n (%) | Clin, n (%) | Ery, n (%) | Azi, n (%) | Doxy, n (%) | Mino, n (%) |
| Moon [54], 2011 | Korea | 100 (30 C. acnes isolates) | 11 (36.7) | 30% | 26.7% | NS | 2 (6.7) | 3 (10) |
| Mendoza [55], 2005, 2006 | Colombia | 100 | 40% | 15% | 35% | NS | 9% | 1% |
| Tan [57], 2007 | Singapore | 262 (174 C. acnes isolates) | 14.9% | 7.5% | 10.3% | NS | 3.4% | 1.7% |
| Yang [58], 2014 | Singapore | 149 (45 C. acnes isolates) | 15 (33%) | 15 (33%) | 14 (31%) | NS | 10 (22%) | NS |
| Luk [56], 2009 | Hong Kong | 111 (86 C. acnes) |
47 (54.7) | 53.5% | 18 (20.9) | NS | 14 (16.3) | 14 (16.3) |
| Abdel-Fattah [53], 2011-2012 | Egypt | 98 patients | NR | 66% | 49% | 5% | 6% | NS |
| Akhawaja [50], 2020 | Jordan | 100 | 55% | 59% | 73% | NS | 37% | 3% |
| Aoki [51], 2013-2018 | Japan | 212 patients (127 C. acnes isolates) | NR | 2013: 37.5% 2018: 56.5% |
2013: 46.9% 2018: 60.9% |
NS | 2013: 0 2018: 4.3% |
2013: 0 2018: 0 |
| Zhu [41], 2015-2017 | China, Kunming | 375 patients (227 C. acnes isolates) | NR | 55.5% | 57.7% | 58.6% | 1.3% | NS |
| Fan [42], 2014 | China, multicenter | 364 patients (312 C. acnes isolates) | NR | NR | 47.8% | 47.8% | 0.3% | 0 |
| Zhang [59], 2016-2017 | China, Shanghai | 100 (63 C. acnes isolates) | NR | 18 (28.6%) | 31 (49.2%) | NS | NS | 0 |
NR: not reported, NS: not studied, Clin: clindamycin resistance, Ery: erythromycin resistance, Azi: azithromycin resistance, Doxy: doxycycline resistance, Mino: minocycline resistance.